Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Glioblastoma
Interventions: CTX-009, CTX-471; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer's Disease and Related Dementias
Interventions: PES-4-BPSD Model, The attention control condition; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Glen Oaks, New York • Manhasset, New York

Conditions: Insulin, Exercise
Interventions: Placebo into the intranasal mucosa, 20 IU NovoLog Insulin aspart into the intranasal mucosa, 40 IU NovoLog Insulin aspart into the intranasal mucosa, 60 IU NovoLog Insulin aspart into the intranasal mucosa, 80 IU NovoLog Insulin aspart into the intranasal mucosa, 100 IU NovoLog Insulin aspart into the intranasal mucosa, 120 IU NovoLog Insulin aspart into the intranasal mucosa; Drug
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Melanoma, Unresectable Melanoma
Interventions: Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Clinically Significant Diabetic Macular Edema
Interventions: ranibizumab; Drug
Lead sponsor: Philip J. ferrone, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Great Neck, New York • Hauppauge, New York

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions: FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Astrocytoma, Glioblastoma
Interventions: CC-90010; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Tampa, Florida • Boston, Massachusetts

Conditions: Spinal Cord Injuries
Interventions: Physical exam and medical history, Assessments, Patient Instruction and use of Device (RePlay); Other · Diagnostic Test · Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Addison, Texas • Richardson, Texas

Conditions: AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 19
States / cities: La Jolla, California • San Francisco, California • Miami, Florida + 12 more

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions: Pembrolizumab, Olaparib, Radiation; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hereditary Cancer-Predisposing Syndrome
Interventions: InheRET, Patient Acceptance, Physician Acceptance Survey; Other
Lead sponsor: InheRET, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Flint, Michigan • Saginaw, Michigan

Conditions: Diabetes, Sedentary Lifestyle
Interventions: Tailored Physical Activity Intervention, Standard of Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pancreatic Neoplasms, Adenocarcinoma
Interventions: Curcumin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brainstem Glioma
Interventions: Capecitabine, Radiation therapy; Drug · Radiation
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions: Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Extensive-Stage Small Cell Lung Cancer
Interventions: sunitinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease (PD)
Interventions: Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Port Charlotte, Florida • Round Rock, Texas

Conditions: Postural Tachycardia Syndrome (POTS)
Interventions: Pulsitile Arterial Tonometry (PAT) Protocol, Calf Blood Flow in Reactive Hyperemia (CBF-RH), Evaluation of Forearm-Mediated Dilation; Procedure · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alzheimer's Disease
Interventions: Semorinemab, Placebo, [18F]GTP1; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery; Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 25 more

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 28
States / cities: Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more

Conditions: Gastric Cancer, Peritoneal Carcinomatosis
Interventions: Cisplatin, Mitomycin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Reducing Behavioral and Psychological Symptoms of Dementia: Hospital Caregivers (Aim 2)

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Technology Development for Physical Rehabilitation of Patients With Upper Extremity Motor Deficits (RePlay)

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

Primary Care-Based Physical Activity for Diabetic Latinas

Trial of Curcumin in Advanced Pancreatic Cancer

A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Effect of Dietary Sodium Intake on Vascular Endothelium

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer